Logo

NABsys Buys Hybridization Company GeneSpectrum to Pursue $1,000 Genome

Dec 22, 2006
NEW YORK (GenomeWeb News) - NABsys, a next-generation sequencing company based in Providence, RI, said today that it has purchased DNA hybridization company GeneSpectrum in an all-stock transaction.
 
NABsys said it will combine GeneSpectrum's probe design and hybridization techniques with its nanopore-based technology, which it has licensed from Brown University, to sequence human DNA at dramatically cheaper rates.
 
NABsys said its goal is to reduce the cost of sequencing a human genome from its current level of $10 million to $1,000 per genome, which the company said would take DNA sequencing from the research lab to the doctor's office.
 
Financial terms of the agreement were not disclosed.
 
John Oliver, co-founder of GeneSpectrum, has been appointed vice president of R&D at NABsys.

Filed under

Clinical Sequencing
Sequencing
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.